Observations from a Hospital Executive (Decision Maker) on the Article “Long-Term Resource Use and Cost of Percutaneous Transluminal Coronary Angioplasty versus Stenting in the Elderly- A Retrospective Claims Data Analysis”
Sep 1, 2003, 00:00 AM
10.1046/j.1524-4733.2003.65003.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60166-0/fulltext
Section Title :
Section Order :
13
First Page :
Coronary stenting has demonstrated superiority to the angioplasty percutaneous transluminal coronary angioplasty (PTCA) in both the restenosis (18% vs. 32%) and revascularization for target vessel in 6 months following the initial procedure (10% vs. 27%). While the initial hospital cost for stenting is higher than the PTCA (owing to the price of the stent), the 1-year follow-up hospital costs for the PTCA eventually catch up with the initial higher cost as shown in a randomized clinical trial by Cohen et al.. There was no accounting for the outpatient and physician costs in this clinical trial. The article by Subramanian et al. in this issue of Value in Health provides us a method of evaluating the initial hospital and 2-year follow-up costs of PTCA vs. stenting using the Medicare claims data. In their analysis, they included the outpatient, physician, skilled nursing facilities, and home health costs. It is a more comprehensive analysis and provides the decision makers a better understanding of the long-term costs associated with these two treatments. The results of the study indicate that there is no significant difference in the initial hospitalization and 2-year follow-up costs comparing the bare metal stenting with the PTCA.
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60166-0&doi=10.1046/j.1524-4733.2003.65003.x
HEOR Topics :
- Cardiovascular Disorders
- Cost/Cost of Illness/Resource Use Studies
- Economic Evaluation
- Retrospective Databases: Electronic Medical and Health Records, Admin Claims
- Specific Diseases & Conditions
- Study Approaches